Development of PARP inhibitors in gynecological malignancies.

scientific article published on 14 March 2017

Development of PARP inhibitors in gynecological malignancies. is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1016/J.CURRPROBLCANCER.2017.02.008
P698PubMed publication ID28583748

P50authorDavid TanQ58821394
P2093author name stringYvonne L E Ang
P433issue4
P304page(s)273-286
P577publication date2017-03-14
P1433published inCurrent Problems in CancerQ15756751
P1476titleDevelopment of PARP inhibitors in gynecological malignancies
P478volume41

Reverse relations

cites work (P2860)
Q47122646Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer
Q93103171Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocarbon Receptor-ABCG2 Axis
Q93053468Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts
Q98164379Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Q52592609Update on PARP Inhibitors in Breast Cancer.

Search more.